Inositol Dose in Pregnancy for Gestational Diabetes

If you are pregnant or planning a pregnancy and looking at inositol, the first thing to know is that this is a different conversation from the general PCOS one. The doses studied in pregnancy, the timing, and the safety questions are specific — and so is the role of your clinician.

This guide covers what clinical trials actually used: doses, when they started, what the evidence supports, and where it still falls short.

Quick answer

In prevention trials, the most studied dose is myo-inositol 2 g twice daily (4 g per day), started in the first trimester, usually alongside folic acid.

The strongest recent synthesis — 12 randomized trials, nearly 4,800 women — found that myo-inositol substantially reduced the risk of gestational diabetes.

Pregnancy is not the moment to self-prescribe. Any inositol use in pregnancy should be discussed with your clinician first.

What the prevention evidence shows

The landmark prevention trial enrolled pregnant women with a parent with type 2 diabetes and gave myo-inositol 2 g plus folic acid 200 mcg twice daily from the end of the first trimester. Gestational diabetes was diagnosed in 6% of the inositol group versus 15% of the placebo group.

A 2026 systematic review and meta-analysis of 12 randomized trials (4,765 women) concluded that myo-inositol substantially reduced the risk of gestational diabetes in women without preexisting diabetes. Most included trials were rated moderate to high quality, with some concerns about bias.

Doses and timing used in trials

Prevention: myo-inositol 2 g twice daily (4 g per day total), typically starting at the first antenatal visit or around 12–13 weeks, often with folic acid.

Treatment after a GDM diagnosis: some cohorts used 4 g per day of myo-inositol as an adjunct to standard care. That evidence is smaller and observational in places, so it should only be considered with clinician oversight.

Folic acid is the non-negotiable

Separate from inositol: the USPSTF recommends 400–800 mcg of folic acid daily for anyone planning or possibly becoming pregnant, to prevent neural tube defects. That recommendation stands regardless of inositol.

Safety and the honest limits of the evidence

Across pregnancy trials, myo-inositol at 2–4 g per day was generally well tolerated, with the usual mild gastrointestinal effects. Inositol's documented safety profile is strongest for the standard studied range.

Professional bodies have not issued a strong, universal recommendation to use myo-inositol for GDM prevention. The evidence is promising but still maturing — which is exactly why clinician discussion matters more here than in the general PCOS context.

Final verdict

If a clinician approves it, myo-inositol 2 g twice daily from early pregnancy is the dose the prevention trials used — and the recent meta-analysis supports the direction of benefit. The evidence is not yet a blanket guideline, so let the decision sit with you and your care team.